Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Dr. Allison Betof Warner from Stanford University joins Rahul Gosain, MD and Rohit Gosain, MD, on the Oncology Brothers podcast to discuss melanoma treatment. The conversation covers the…
NEW YORK (Reuters Health) – Compared with zoledronic acid, the monoclonal antibody denosumab is more effective in delaying skeletal-related events in women with breast cancer that has metastasized…
NEW YORK (Reuters Health) – The tyrosine kinase inhibitors gefitinib or erlotinib may slow the development of central nervous system metastases in patients with advanced non-small cell lung…
NEW YORK (Reuters Health) – Women with breast cancer treated with anthracycline-taxane based regimens are more likely to become amenorrheic than women treated with just anthracyclines or conventional…
NEW YORK (Reuters Health) – After first-line treatment with bevacizumab plus interferon-alpha2a, subsequent therapy with tyrosine kinase inhibitors (TKIs) improves survival in patients with metastatic renal cell carcinoma,…
NEW YORK (Reuters Health) – High-dose chemo followed by autologous stem-cell transplantation achieves good results in patients with relapsed Hodgkin’s lymphoma, and outcomes are not improved by additional…
NEW YORK (Reuters Health) – In order to minimize the risk of potential harms, erythropoiesis-stimulating agents (ESAs) in patients undergoing myelosuppressive chemotherapy should be administered at the lowest…
NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to state-of-the-art adjuvant chemotherapy for stage II or III colon cancer does not improve disease-free survival, according…
NEW YORK (Reuters Health) – Rofecoxib used as adjuvant therapy does not improve survival or reduce recurrences in patients who have undergone surgery for colorectal cancer, according to…
NEW YORK (Reuters Health) – Adding interferon alpha-2b and megadose vitamins to treatment with intravesical BCG does not improve outcomes in patients with non-muscle invasive bladder cancer. In…
NEW YORK (Reuters Health) – The tyrosine-kinase inhibitor pazopanib seems to be a promising option for treating progressive metastatic differentiated thyroid cancer that is unresponsive to radioiodine therapy,…
